A Randomized Clinical Trial of ab Interno Canaloplasty and Trabeculotomy With the OMNI Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients With Primary Open Angle Glaucoma

A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)

Start Date21 Aug 2024

Sponsor / Collaborator

Sight Sciences, Inc.

NCT06730516

/ CompletedEarly Phase 1IIT

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

Start Date24 Jun 2024

Sponsor / Collaborator

Zagazig University

100 Clinical Results associated with Latanoprost

100 Translational Medicine associated with Latanoprost

100 Patents (Medical) associated with Latanoprost

2,139

Literatures (Medical) associated with Latanoprost

14 Jan 2025·Investigative Ophthalmology & Visual Science

Relationship Between Intraocular Pressure and the True Rate of Functional and Structural Progression in the United Kingdom Glaucoma Treatment Study

Article

Author: Montesano, Giovanni ; Ometto, Giovanni ; Garway-Heath, David F. ; Rabiolo, Alessandro ; Crabb, David P.

PurposeTo investigate the effect of average intraocular pressure (IOP) on the true rate of glaucoma progression (RoP) in the United Kingdom Glaucoma Treatment Study (UKGTS).MethodsUKGTS participants were randomized to placebo or Latanoprost drops and monitored for up to two years with visual field tests (VF, 24-2 SITA standard), IOP measurements, and optic nerve imaging. We included eyes with at least three structural or functional assessments (VF with <15% false-positive errors). Structural tests measured rim area (RA) with Heidelberg retina tomography (HRT) and average peripapillary retinal nerve fiber layer (pRNFL) thickness with optical coherence tomography (OCT). One eye of 436 patients (222 on Latanoprost) was analyzed. A Bayesian hierarchical model estimated the true RoP of VF and structural metrics, and their correlations, using sign-reversed multivariable exponential distribution. RA and pRNFL measurements were converted to a dB scale, matching the VF metric (mean deviation [MD]). The effect of average IOP on the true RoPs was estimated.ResultsTrue RoP at the mean average IOP (17 mm Hg) was faster (P < 0.001) for VF-MD (-0.59 [-0.73, -0.48] dB/year) than HRT-RA (-0.05 [-0.07, -0.03] dB/year) and OCT-pRNFL (-0.08 [-0.11, -0.06] dB/year). The proportional acceleration of RoP per mm Hg increase was, however, not significantly different (smallest P = 0.15). Accounting for the structural floor-effect largely eliminated the differences in RoPs (smallest P = 0.25).ConclusionsVF appeared to deteriorate at a faster rate than structural measurements. However, this could be explained by the floor-effect from nonfunctional tissue. IOP induced a similar acceleration in RoP per mm Hg increase.

01 Jan 2025·Ophthalmology Science

Subconjunctival Administration of an Adeno-Associated Virus Expressing Stanniocalcin-1 Provides Sustained Intraocular Pressure Reduction in Mice

Article

Author: Rinkoski, Tommy A ; Kohli, Darrell ; Roddy, Gavin W. ; Anderson, Kjersten J ; Omer, Mohammed E ; Fautsch, Michael P. ; Chowdhury, Uttio Roy ; Anderson, Kjersten J. ; Fautsch, Michael P ; Rinkoski, Tommy A. ; Niknam, Parvin ; Pacheco Marrero, Johann M. ; Omer, Mohammed E. ; Pacheco Marrero, Johann M ; Roddy, Gavin W

PurposeTo investigate subconjunctival administration of a single-stranded, adeno-associated virus, serotype 2, engineered to express stanniocalcin-1 with a FLAG tag (ssAAV2-STC-1-FLAG) as a novel sustained (IOP) lowering agent with a reduced ocular surface side effect profile.DesignIn vivo preclinical investigation in mice.SubjectsC57BL/6J, DBA/2J, prostaglandin F (FP) receptor knockout mice.MethodsNormotensive C57BL/6J mice were treated with a subconjunctival injection of ssAAV2-STC-1-FLAG (2 μL; 6 × 10⁹ viral genomes [VGs]) in 1 eye and the same volume and concentration of ssAAV2-green fluorescent protein (GFP) or the same volume of phosphate-buffered saline in the fellow eye. Ocular hypertensive DBA/2J mice were subconjunctivally injected with 6 × 10⁹ VGs of ssAAV2-STC-1-FLAG or ssAAV2-GFP. Steroid-mediated ocular hypertension was induced in C57BL/6J mice with weekly injections of dexamethasone into the conjunctival fornix, and mice were then injected subconjunctivally with 6 × 10⁹ VGs of ssAAV2-STC-1-FLAG or ssAAV2-GFP. Prostaglandin F receptor knockout mice were injected subconjunctivally with 6 × 10⁹ VGs of ssAAV2-STC-1-FLAG or phosphate-buffered saline. An identical vector was constructed without the FLAG tag (ssAAV2-STC-1) and evaluated in normotensive C57BL/6J mice. Intraocular pressure was assessed using the Tonolab tonometer for all experiments. Tumor necrosis factor alpha (TNFα), a marker of ocular surface inflammation, was compared between subconjunctivally delivered ssAAV2-STC-1-FLAG and other treatments including daily topical latanoprost.Main Outcome MeasuresIntraocular pressure assessment.ResultsSubconjunctival delivery of ssAAV2-STC-1-FLAG significantly reduced IOP for 10 weeks post injection in normotensive mice. Maximal IOP reduction was seen at week 3 postinjection (17.4%; 17.1 ± 0.8 vs. 14.1 ± 0.8 mmHg, P < 0.001). After the IOP-lowering effect had waned, a second injection restored the ocular hypotensive effect. Subconjunctivally delivered ssAAV2-STC-1-FLAG lowered IOP in DBA/2J mice (16.9%; 17.8 ± 2.0 vs. 14.8 ± 0.9 mmHg, P < 0.001) and steroid-mediated ocular hypertensive mice (20.0%; 19.0 ± 0.6 vs. 15.2 ± 0.7 mmHg, P < 0.001) over the experimental period. This construct also reduced IOP to a similar extent in wild-type (15.9%) and FP receptor knockout (15.7%) mice compared with the fellow eye. A related construct also lowered IOP without the FLAG tag in a similar manner. Reduction in conjunctival TNFα was seen when comparing subconjunctivally delivered ssAAV2-STC-1-FLAG to daily topical latanoprost.ConclusionsSubconjunctival delivery of the STC-1 transgene with a vector system may represent a novel treatment strategy for sustained IOP reduction and improved ocular tolerability that also avoids the daily dosing requirements of currently available medications.Financial DisclosuresProprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

01 Jan 2025·Ecotoxicology and Environmental Safety

High-resolution observation per 1.5 h revealed prominent time-dependent daily contamination variations of p-phenylenediamine (PPD) antioxidants and their quinone derivatives PPDQs in PM2.5 from central China

Article

Author: Zhang, Yanhao ; Zhang, Shusheng ; Ren, Lishun ; He, Qingyun ; Hou, Shijiao ; Su, Fangcheng ; Cai, Zongwei ; Peng, Zifang ; Yin, Dan ; Pei, Congcong ; Huang, Yanjie

p-Phenylenediamine (PPD) antioxidants and their quinone derivatives (PPDQs), as hot-spot novel contaminants in recent years, have been detected in air fine particulate matters (PM_2.5) in multiple regions. However, current research all discussed the pollution of PPDs and PPDQs based on the collected PM_2.5 samples at least in one day (23.5 h). In this work, an innovative study was conducted to investigate their precise daily pollution characteristics and health risks based on high-resolution collected PM_2.5 samples every 1.5 hours in one week in Zhengzhou, a megacity continuously suffers from serious air contamination in central China. The composition patterns and sources of PPDs and PPDQs were discovered and more serious contamination of them were both found at the day-time (07:00-19:00). Almost all daily time intervals with relatively high pollution levels of PPDs and PPDQs were commuting time for majority of workers, which was possibly because of increased rubber tire abrasion induced by huge traffic volume. The highest daily adults' inhalation risks were also found in 11:30-13:00 and 16:00-17:30 for PPDs and PPDQs in PM_2.5, respectively. Current study builds the relationship between pollution status of such novel pollutants and human activities, and possibly guides people in central China to take precautions to protect themselves from environmental toxicants at special daily time.

News (Medical) associated with Latanoprost

02 Dec 2024

·www.globenewswire.com

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Press ReleaseNicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont BlancNCX 470 partnering efforts will focus on routes for bringing the product to market in the U.S.Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 December 2, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension, is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the U.S. for the trial was announced in July 2024 and therefore the target number of patients to be enrolled in the Denali trial has been met. Topline results are expected in Q3 2025.“Following completion of the recruitment of the Denali trial in the United States, we have seen an acceleration in the number of Chinese patients randomized in this multi-center international trial, allowing us to close Chinese patient recruitment earlier than expected.” said Doug Hubatsch, Chief Scientific Officer of Nicox. “I would like to thank the teams at both Nicox and Ocumension and the clinical staff and patients at our sites, as well as our partner organisations for their dedication through the final stages of the recruitment. We look forward to announcing the topline results in Q3 next year. Whilst we continue the final stages of this trial, we are also completing the additional development steps necessary to support the preparation of New Drug Applications in both the United States and China to ensure that these could be submitted as soon as possible after the receipt of the Denali topline data.” “NCX 470 continues to generate interest from potential commercialisation partners. With strong collaborations in Japan, China, Korea and Southeast Asia already in place, we are focussing on the route to commercialisation for NCX 470 in the United States, with potential for regional partnerships elsewhere.” added Emmet Purtill, VP Business Development. The Denali trial is evaluating the intraocular pressure (IOP) lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension. It is a multi-country (U.S. and China) clinical trial financed equally by Nicox and Ocumension, Nicox’s exclusive licensee for China, Korea and Southeast Asia. The Denali trial, together with the Mont Blanc trial, was designed to fulfill the clinical regulatory requirements to support New Drug Application (NDA) submissions of NCX 470 in the U.S. and China. The company estimates that a U.S. NDA for NCX 470 could potentially be submitted in H1 2026, subject to the company entering into a partnership for the commercialization of NCX 470 in the U.S. or obtaining appropriate financing.Topline results from the first Phase 3 trial, Mont Blanc, showed the IOP-lowering effect from baseline was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for latanoprost. Statistical non-inferiority was met vs. latanoprost in the primary efficacy analysis and 4 out of 6 timepoints additionally demonstrated superiority; the trial therefore met the efficacy requirements for approval in the U.S. NCX 470 was well tolerated and discontinuation rates were low. The results of the Mont Blanc trial have been published in the prestigious American Journal of Ophthalmology, and numerous post hoc analyses have been presented. Full details of all presentations and publications can be found at nicox.com/pipeline-markets-and-science/#publications.About NCX 470NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent IOP lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase. NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is the leading branded PGA. PGAs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_DenaliLastPatient_PR_20241202_FINAL

Phase 3Clinical ResultLicense out/in

19 Nov 2024

·www.globenewswire.com

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification of the optimal dose of NCX 470 in the Mont Blanc trial, the first Phase 3 trial of NCX 470Both doses of NCX 470 ophthalmic solution tested, 0.065% and 0.1%, lowered intraocular pressure more than the comparator, latanoprost 0.005% ophthalmic solutionThe 0.1% NCX 470 concentration was chosen for the remainder of the Mont Blanc trial and the ongoing Denali trial based on a greater intraocular pressure reduction compared to the 0.065% concentration and a good safety profile November 18, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the design details and results of the adaptive design period of the NCX 470 Mont Blanc Phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online in Contemporary Clinical Trials, Volume 147, 2024, 107730 (online pre-publication https://doi-org.libproxy1.nus.edu.sg/10.1016/j.cct.2024.107730). A portion of this data has previously been presented as a poster at the 2023 World Glaucoma Congress. The dose finding Phase 2 trial (Dolomites) tested NCX 470 at several concentrations and the results suggested that a higher dose than those tested might provide even better efficacy and safety profile. To test this, concentrations of 0.065% and 0.1% were included in an adaptive dose selection period of the Phase 3 Mont Blanc trial, which compared the safety and efficacy of NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution in adult subjects with open-angle glaucoma or ocular hypertension. At the Week 2 timepoint, the least-squares mean difference in diurnal intraocular pressure (IOP) compared to latanoprost were 1.51 mmHg for NCX 470 0.065 % group (p = 0.0308) and 1.71 mmHg for NCX 470 0.1 % group (p = 0.0123), in favor of NCX 470. The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05).The adaptive dose selection period was used in place of additional dose ranging studies to select the 0.1% concentration of NCX 470 for the completion of the Mont Blanc clinical trial as well as the second Phase 3 trial, Denali.The results of the Mont Blanc trial were announced in October 2022. The second Phase 3 trial of NCX 470, Denali, is ongoing and topline results are expected in the third quarter of 2025.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_MontBlancAdaptiveDesignPublication_PR_FINAL

Phase 3Clinical ResultPhase 2

31 Oct 2024

·www.prnewswire.com

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") in Portugal, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative medicine for the treatment of inflammation and pain following ocular surgery. DÁVI is a trusted partner of Pharmathen Global Holding B.v., AZAD Pharma AG, NTC S.r.l. and Pfizer through marketing and promotion of Xalacom© (Latanoprost + Timolol) and Xalatan© (Latanoprost) for more than 12 years. DÁVI is one of the key players in the Portuguese Market, with over 100 years' history in the distribution and promotion of branded ophthalmology products. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was recently launched in the United States in September, 2024. The DÁVI licensing agreement includes upfront, commercialization milestones, and sales milestones, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a recent survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. APP13007 anticipates significant potential in Portugal, which has around 90,000 cataract surgeries, annually, as reported by Eurostat. "This partnership with DÁVI Farmacêutica, marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery." said Erick Co, President and CEO of Formosa Pharmaceuticals. Rui Alves, Business Development Manager of DÁVI Farmacêutica, stated, "We are excited at DÁVI to be partnering with Formosa and have the opportunity to offer this cutting-edge drug and technology to our ophthalmologists and patients, reinforcing our strong position in the market and the commitment to enhance the well-being of our people." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit . About DÁVI Farmacêutica DÁVI Farmacêutica, is a century-old company and one of the key players in ophthalmology and ENT segments in Portugal. The company's core activities are the distribution & promotion of branded medicines with significant partnerships with major multinational pharmaceutical companies. Our daily mission is to give our patients the best option available in the market, making their lives better. To know more about DÁVI Farmacêutica, visit . SOURCE Formosa Pharmaceuticals Inc., WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inDrug Approval

100 Deals associated with Latanoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D00356	Latanoprost	S01EE01	DB00654

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Viatris, Inc.	12 Mar 1999
Glaucoma, Open-Angle	US	Upjohn US 2 LLC	05 Jun 1996
Ocular Hypertension	US	Upjohn US 2 LLC	05 Jun 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 1	US	Sun Pharmaceutical Industries Ltd.	12 Sep 2018
Glaucoma, Open-Angle	Discovery	US	Sun Pharmaceutical Industries Ltd.	12 Sep 2018
Ocular Hypertension	Discovery	US	Sun Pharmaceutical Industries Ltd.	12 Sep 2018
Glaucoma	Discovery	US	Viatris, Inc.	01 Jul 2008
Glaucoma	Discovery	DE	Viatris, Inc.	01 Jul 2008
Glaucoma	Discovery	GB	Viatris, Inc.	01 Jul 2008
Glaucoma	Discovery	UA	Viatris, Inc.	01 Jul 2008
Glaucoma	Discovery	SK	Viatris, Inc.	01 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04133311 (CTgov)	Phase 3	Glaucoma, Open-Angle	386	DE-130A (DE-130A)	ibclvqejct(kjszhfckjc) = qonsddywfy ctdvoikgzu (rztepszong, miqcjzvxfm - lgjgceyqlh) View more	-	28 May 2024
				Xalatan® (Xalatan®)	ibclvqejct(kjszhfckjc) = nneckwvcva ctdvoikgzu (rztepszong, nnywhjopzd - ydksjkneuh) View more
APAO2024	Not Applicable	Ocular Hypotension	-	Omidenepag Isopropyl (OMDI) 0.002%	rfmsxixxib(afdejnsbyo) = zkmgxzubpm gidsodukca (vshwogsqph, 3.31)	-	22 Feb 2024
				Latanoprost	rfmsxixxib(afdejnsbyo) = jusuliixcp gidsodukca (vshwogsqph, 2.12)
EURETINA2023	Not Applicable	Uveal Effusion Syndrome	-	Topical Latanoprost	gqkktcepeh(gakrdcuqnu) = exacerbation of uveal effusion in nanophthalmic eyes xtyjxpixux (pmmxwnreqg )	-	05 Oct 2023
				Topical Corticosteroids
NCT04405245 (CTgov)	Phase 2	Glaucoma, Open-Angle	194	AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% QD + Latanoprost)	lrrnfdjvvk(lbowmjudqn) = diqpayuhso ljnccpohmn (ehvtzqryki, ibrhpenjps - mjdblnbhnq) View more	-	25 May 2023
				AKB-9778 4%+Latanoprost ophthalmic solution (AKB-9778 4% BID + Latanoprost)	lrrnfdjvvk(lbowmjudqn) = wlbxemnwkd ljnccpohmn (ehvtzqryki, wtbswpaflc - cpzxeumhej) View more
ARVO2023	Not Applicable	Glaucoma	107	Preservative-free surfactant-free latanoprost eyedrop	fuqzihvigu(vnzqghjaqn) = njcecollrk gpvffjdkql (urzteyckco )	-	23 Apr 2023
NCT02981446 (PEONY, AAO2021)	Phase 3	Ocular Hypertension	185	Omidenepag Isopropyl 0.002%	(uktkztkdlp) = bflcgpsslt dqcnxvtoxn (ijsvcgpxuc, 2.3)	Positive	14 Nov 2021
				Latanoprost 0.005%	(uktkztkdlp) = tqnvidvcef dqcnxvtoxn (ijsvcgpxuc, 2.1)
NCT03949244 (CTgov)	Phase 4	Glaucoma, Open-Angle	47	Nailfold capillaroscopy+Latanoprost 0.005% (Latanoprost 0.005%)	mpjwociage(tsymsfkpqf) = bhyicelvjc xkikkvgvje (tdkygihsgj, wzvkmddqhu - varrzuhqum) View more	-	23 Aug 2021
				Nailfold capillaroscopy+Latanoprost bunod 0.024% (Latanoprost Bunod 0.024%)	mpjwociage(tsymsfkpqf) = sylnllfkka xkikkvgvje (tdkygihsgj, lxdicmoaql - cwqkcerrmr) View more
EDEN consortium (ARVO2021)	Not Applicable	-	106	Latanoprost	(jlqyqccgzk) = rbtjvkwrnz zgyadmixex (qurjnccwvl )	Negative	01 Jun 2021
				Timolol	(jlqyqccgzk) = mxqaclyrxx zgyadmixex (qurjnccwvl )
NCT00934089 (CTgov)	Phase 2	Glaucoma, Open-Angle	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	dcuhedokvu(nzgxsxcvso) = xtfvozkhxw jfazddiukk (zuoxbwpxed, kpyzbzrwtu - gamabcfkqx) View more	-	03 May 2021
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	dcuhedokvu(nzgxsxcvso) = mfivmemjci jfazddiukk (zuoxbwpxed, vbnudxbrgn - tsuabvfxet) View more
NCT02466399 (CTgov)	Phase 2	Glaucoma, Open-Angle	80	POLAT-001 (POLAT-001)	nlsmvfaovq(uxspfiyzwu) = qnjxqohwku pmjskkyyhv (fksrslhqdu, flsfyxsoqm - kftrexrisk) View more	-	16 Nov 2020
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	nlsmvfaovq(uxspfiyzwu) = pvxwcfpgem pmjskkyyhv (fksrslhqdu, cwrwzmmilu - uzguqlvmty) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis